{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.03","upperLimit":"19.81","value":"14.91"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"96"}],"units":"Participants"}],"description":"Duration of Objective Response was defined as the number of months from the date of the first disease response (clinical complete response \\[CCR\\], or partial response \\[PR\\]) (later confirmed) until the date of progression and was determined using Kaplan-Meier product-limit estimates. In this analysis, pts who did not progress were censored as of their last evaluation with an OPDREC assessment.","dispersionType":"Full Range","groups":[{"description":"Regimen was 14 mg/m2 IV over a 4-hour period on Days 1, 8, and 15 of a 28-day cycle. The protocol included 6 cycles of treatment; responding patients and patients who achieved at least Stable Disease (SD) had the option of continuing treatment beyond 6 cycles at the discretion of the Investigator and based on local regulations.","id":"OG000","title":"Romidepsin"}],"paramType":"MEDIAN","populationDescription":"Efficacy analysis based on interim analysis of data for as treated population","reportingStatus":"POSTED","timeFrame":"Up to 10 months; median duration of follow up was 5.1 months","title":"Duration of Objective Disease Response","type":"SECONDARY","unitOfMeasure":"Months"}